Literature DB >> 27604385

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

N I Cherny, R Sullivan, U Dafni, J M Kerst, A Sobrero, C Zielinski, E G E de Vries, M J Piccart.   

Abstract

Entities:  

Year:  2017        PMID： 27604385     DOI： 10.1093/annonc/mdw258

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

Review 1.  Targeted therapies for renal cell carcinoma.

Authors:  Edwin M Posadas; Suwicha Limvorasak; Robert A Figlin
Journal:  Nat Rev Nephrol       Date:  2017-07-10       Impact factor: 28.314

2.  Physicians' Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer.

Authors:  Yi Zhang; Miao Liu; Houpu Yang; Shu Wang
Journal:  Breast Care (Basel)       Date:  2021-08-20       Impact factor: 2.268

Review 3.  Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?

Authors:  Giovanni Barosi; Robert Peter Gale
Journal:  Leukemia       Date:  2019-01-28       Impact factor: 11.528

Review 4.  Targeted α Therapies for the Treatment of Bone Metastases.

Authors:  Fable Zustovich; Roberto Barsanti
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

5.  The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.

Authors:  Helmy M Guirgis
Journal:  J Immunother Cancer       Date:  2018-02-20       Impact factor: 13.751

6.  Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study.

Authors:  Qian Jiang; Wei Zeng; Jiajie Yu; Hui Liu; Mian Mao; Youping Li
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

7.  Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors:  Antonio Cuneo; Robin Foà
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

8.  The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.

Authors:  Assaf Moore; Ido Stav; Robert B Den; Noa Gordon; Michal Sarfaty; Victoria Neiman; Eli Rosenbaum; Daniel A Goldstein
Journal:  J Oncol       Date:  2019-01-02       Impact factor: 4.375

9.  Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.

Authors:  Gabor Liposits; Henrik Rode Eshøj; Sören Möller; Stine Brændegaard Winther; Halla Skuladottir; Jesper Ryg; Eva Hofsli; Carl-Henrik Shah; Laurids Østergaard Poulsen; Åke Berglund; Camilla Qvortrup; Pia Österlund; Bengt Glimelius; Halfdan Sorbye; Per Pfeiffer
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Improving Quality and Value of Cancer Care for Older Adults.

Authors:  Erika E Ramsdale; Valerie Csik; Andrew E Chapman; Arash Naeim; Beverly Canin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.